Agios Pharma (AGIO): Buy The ASH Pullback - Needham

Needham & Company analyst, Chad Messer, reiterated his Buy rating on shares of Agios Pharma (NASDAQ: AGIO) after shares traded down 13% over safety concern from a single patient with cholestatic hepatitis on AG-519 even though this occurred at 6x+ the likely goforward dose.

Agios presented multiple updates over the weekend and through Monday at ASH, nearly all of which the analyst views as incrementally positive. The analyst believes Agios will be able to reliably pick out responders to their PK activators and use dose titration to safely get patients to a hemoglobin response.

No change to the price target of $60.

For an analyst ratings summary and ratings history on Agios Pharma click here. For more ratings news on Agios Pharma click here.

Shares of Agios Pharma closed at $49.88 yesterday.

You May Also Be Interested In

• OncoCyte Corp (OCX) PT Raised to $4.25 at Needham
• Compass Minerals International (CMP) PT Lowered to $15 at Deutsche Bank
• KKR Real Estate Financial Trust (KREF) PT Lowered to $12 at JMP Securities